October 30, 2013
1 min read

VMA does not affect anti-VEGF treatment for polypoidal choroidal vasculopathy

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The presence of vitreomacular adhesion had an insignificant effect on visual outcomes after intravitreal anti-VEGF injections for the treatment of polypoidal choroidal vasculopathy, according to a study.

The retrospective study included 104 eyes of 102 patients with polypoidal choroidal vasculopathy. Eyes were assigned to two groups; 23 eyes had vitreomacular adhesion (VMA) and 81 eyes did not have VMA.

Investigators compared logMAR best corrected visual acuity and central macular thickness between the groups at baseline and at 1, 3, 6 and 12 months after anti-VEGF treatment.

At final follow-up, eyes in the VMA group had received an average of 4.82 anti-VEGF injections and eyes in the non-VMA group had received an average of 4.92 injections.

Mean logMAR BCVA improved from 0.81 to 0.67 in the VMA group (P = .01) and from 0.79 to 0.64 in the non-VMA group (P = .02).

Average central macular thickness decreased from 354.4 µm to 249.6 µm in the VMA group and from 361.2 µm to 267.3 µm in the non-VMA group (both P = .01).

Polyps regressed in five eyes (21.7%) in the VMA group and 18 eyes (22.2%) in the non-VMA group.

“There was no statistically significant difference in the best corrected visual acuity improvement, central macular thickness improvement and polyp regression rate between the groups,” the study authors said.

Disclosure: The study authors have no relevant financial disclosures.